Best practices in scleroderma: An analysis of practice variability in SSc centres within the Canadian Scleroderma Research Group (CSRG)

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.71, 2012, Pages

  Harding, Sarah ^a   Khimdas, Sarit ^a   Bonner, Ashley ^b   Baron, Murray ^c   Pope, Janet ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Best practice; Guidelines; Practice variability; Scleroderma; SSc

Indexed keywords

ANTIARRHYTHMIC AGENT; AZATHIOPRINE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYCHLOROQUINE; ILOPROST; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; SITAXSENTAN; TREPROSTINIL; WARFARIN;

ARTHRITIS; ARTICLE; CLINICAL EVALUATION; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DYSPHAGIA; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; ESOPHAGUS DILATATION; FEMALE; FINGER ULCER; FORCED VITAL CAPACITY; HEART ARRHYTHMIA; HUMAN; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MYOSITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SCLERODERMA; SKIN DISEASE; THORAX RADIOGRAPHY;

BENCHMARKING; CANADA; CONSENSUS; DATABASES, FACTUAL; DIAGNOSTIC TESTS, ROUTINE; EVIDENCE-BASED MEDICINE; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; QUALITY INDICATORS, HEALTH CARE; RHEUMATOLOGY; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84867347314     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. THOMPSON AE, POPE JE Increased prevalence of scleroderma in southwestern Ontario: a cluster analysis. J Rheumatol 2002; 29: 1867-73.
2. GAZI H, POPE JE, CLEMENTS P et al. Outcome measurements in scleroderma: results from a Delphi exercise. J Rheumatol 2007; 34: 501-9.
3. CLEMENTS PJ, FURST DE, WONG WK et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999; 42: 1194-203.
4. LEIGHTON C Drug treatment of scleroderma. Drugs 2001; 61: 419-27.
5. POPE JE, BELLAMY N, SEIBOLD JR et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351-8.
6. KOWAL-BIELECKA O, LANDEWÉ R, AVOUAC J et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620-8.
7. POPE JE Connective tissue diseases: New evidence-based guidelines for treating SSc. Nat Rev Rheumatol 2009; 5: 300-2.
8. HACHULLA E, DE GROOTE P, GRESSIN V et al. The tree-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009; 60: 1831-9.
9. POPE JE, OUIMET JM, KRIZOVA A Scleroderma treatment differs between experts and general rheumatologists. Arthritis Rheum 2006; 55: 138-45.
10. SAPADIN AN, FLEISCHMAJER R Treatment of scleroderma. Arch Dermatol 2002; 138: 99-105.
11. FRIES R, SHARIAT K, VON WILMOWSKY H, BOHM M Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005; 112: 2980-5.
12. HERRICK AL, VAN DEN HOOGEN F, GABRIELLI A et al. Modified-release sildenafil reduces Raynauds attack frequency in systemic sclerosis (abstract). Arthritis Rheum 2009; 60 (Suppl. 10): 472.
13. NIHTYANOVA SI, BROUGH GM, BLACK CM, DENTON CP Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford) 2007; 46: 442-5.
14. LIOSSIS SN, BOUNAS A, ANDONOPOULOS AP Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 2006; 45: 1005-8.
15. POPE JE, LEE P, BARON M et al. Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 2005; 32: 1273-8.